No connection

Search Results

KROS vs SLN

KROS
Keros Therapeutics, Inc.
NEUTRAL
Price
$11.21
Market Cap
$341.4M
Sector
Healthcare
AI Confidence
80%
SLN
Silence Therapeutics plc
BEARISH
Price
$7.53
Market Cap
$355.7M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
KROS
4.87
SLN
--
Forward P/E
KROS
-2.22
SLN
-10.46
P/B Ratio
KROS
0.72
SLN
5.71
P/S Ratio
KROS
1.4
SLN
636.26
EV/EBITDA
KROS
-0.69
SLN
-12.02

Profitability

Gross Margin
KROS
47.91%
SLN
61.54%
Operating Margin
KROS
-7576.62%
SLN
-37150.0%
Profit Margin
KROS
35.65%
SLN
0.0%
ROE
KROS
19.9%
SLN
-90.27%
ROA
KROS
9.25%
SLN
-30.79%

Growth

Revenue Growth
KROS
-87.3%
SLN
-99.9%
Earnings Growth
KROS
--
SLN
--

Financial Health

Debt/Equity
KROS
0.06
SLN
0.0
Current Ratio
KROS
15.45
SLN
8.72
Quick Ratio
KROS
15.1
SLN
8.06

Dividends

Dividend Yield
KROS
--
SLN
--
Payout Ratio
KROS
0.0%
SLN
0.0%

AI Verdict

KROS NEUTRAL

KROS presents a stark dichotomy between a perfect Piotroski F-Score (9/9) and collapsing fundamental growth. While the balance sheet is exceptionally strong with a current ratio of 15.45 and minimal debt, the company is experiencing a severe revenue contraction of -87.30% and extreme operating losses. The stock is significantly undervalued relative to its Graham Number ($28.33) and Intrinsic Value ($16.1), but this value is offset by bearish insider activity and a negative technical trend.

Strengths
Perfect Piotroski F-Score (9/9) indicating strong short-term financial improvement
Exceptional liquidity with a Current Ratio of 15.45
Very low leverage with a Debt/Equity ratio of 0.06
Risks
Catastrophic revenue decline of -87.30% YoY
Extreme operating inefficiency with an operating margin of -7576.62%
Bearish insider sentiment with sales from CEO, CFO, and General Counsel
SLN BEARISH

SLN exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical financial weakness. The company has experienced a catastrophic revenue collapse of -99.90% YoY, rendering traditional valuation metrics like the P/S ratio (636.26) meaningless. While the current ratio of 8.72 suggests a temporary liquidity cushion, the operating margin of -37,150% and negative ROE of -90.27% signal an unsustainable burn rate. The recent price surge is entirely decoupled from financial performance and appears purely speculative.

Strengths
High current ratio (8.72) providing short-term liquidity
Zero debt (Debt/Equity 0.00) reducing insolvency risk from leverage
Positive gross margin (61.54%) suggesting potential for product viability
Risks
Near-total collapse of revenue (-99.90% YoY)
Extreme operational inefficiency (Operating Margin -37,150%)
Critical financial health score (Piotroski 1/9)

Compare Another Pair

KROS vs SLN: Head-to-Head Comparison

This page compares Keros Therapeutics, Inc. (KROS) and Silence Therapeutics plc (SLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile